Biomedical subjects

Hisashi Furue

Publications and source records attributed to Hisashi Furue.

5 recordsLinked to original sources

PubMed2005

[Oxaliplatin].

Oxaliplatin (L-OHP) is a new third generation 1,2-DACH-platinum derivative. Pre-clinical studies from human cell lines suggested that L-OHP was efficacious in treating advanced or recurrent colorectal cancer. Furthermore, L-OHP and fluorouracil combination was shown to be synergistic both in experimental studies and in clinical trials. Toxicity profiles also differ from other platinum derivatives. Neurotoxicity is much more frequent, but renal toxicity, alopecia, and ototoxicity are less. Combination chemotherapy with L-OHP, infusional 5-fluorouracil, and leucovorin-a treatment regimen known as FOLFOX, has been shown clinical benefit in response rate, time to progression, and overall survival as compared to those achieved with 5-fluorouracil+leucovorin. Thus, introduction of irinotecan and L-OHP into clinical use has been a major advances for patients with metastatic colorectal cancer. Additional research must be required to define optimal dose schedule and sequence of these agents. Inducing remission with first-line treatment has been shown a significant correlation between tumor response and survival (progression free and overall).

Animals↗

PubMed2003

[Adverse effects in cancer chemotherapy].

The toxicity of cancer treatment affects adversely the QOL of patients and limits the intensity of treatment that can be administered. In this article, characteristics of these each adverse reactions are described. In the last decade, several means have been developed that offer possible prevention and reduction from the adverse effects of a range of cancer treatment. Furthermore, recently, practice guidelines are systematically developed to assist the practitioner and patients decision about appropriate management for specific clinical circumstances. However, it is important to realize that these guidelines cannot always account for individual variation among patients. 'Close clinical monitoring, early recognition of toxicities and toxicity syndromes, aggressive therapeutic interventions, and withholding therapy in the presence of severe treatment related toxicities' is always required.

Antineoplastic Agents↗

PubMed2003

[Chemotherapy cancer treatment during the past sixty years].

Although history of cancer chemotherapy is relatively short, its role is expanding. Cancer chemotherapy provides variably effective treatment for the majority of human cancer and curative treatment for some categories of cancer. The role of chemotherapy will expand further and play an even greater role in improving both the survival and quality of life for patients with cancer. This progress has resulted from many scientific efforts, including drug development, pharmacology, preclinical experiment, quantitative criteria for response and series of clinical trials in which the importance of dose schedule, of sequencing chemotherapeutic agents, and particularly of combination chemotherapy was studied. While these progress has been substantial, we still have a long way to go. The current studies in basic tumor biology, clinical innovations, and the interaction between host and tumor provide real progress in the treatment of cancer.

Antineoplastic Agents↗

PubMed2002

[Clinical usefulness of ondansetron injection in patients receiving cancer chemotherapy].

Before and after launch of 5-HT3, antagonist, necessary dose and duration of chemotherapy were compared between the patients who were confirmed to have undergone chemotherapy before the launch of 5-HT3 antagonist (retrospective group) and the ones currently using ondansetron (OND) for chemotherapy-induced emesis (prospective group). Clinical usefulness of OND was evaluated through survey on quality of life (QOL) to patients and questionnaires to physicians, nurses & patients. Necessary dose of chemotherapy was evaluated by investigating actual dose of cisplatin (CDDP). As the result, necessary dose of CDDP was confirmed to be different between retrospective and prospective groups. The influence on the actual CDDP dose was observed with or without use of G-CSF or by recommended dose of CDDP, while no influence by 5-HT3 antagonist was observed. For necessary duration of chemotherapy, significant difference was not observed between retrospective or prospective groups. On the other hand, actual CDDP dose or necessary duration of chemotherapy were confirmed to be greatly affected by chemotherapy-induced adverse events such as blood disorder (e.g. bone marrow suppression) or renal disorder, rather than chemotherapy-induced emesis. As the result of QOL survey to patients and other questionnaires to medical staff & patients, the fact of chemotherapy-induced emesis to lower the patient's QOL as well as the importance of emetic control was confirmed. It was also confirmed that the workload of nurses or other medical staff has lessened since the launch of 5-HT3 antagonists.

Adult↗

PubMed2002

[Prevention of side reactions--present status and problems--special references].

The toxicity of chemotherapy affects adversely the QOL of patients and limits the dose of chemotherapy that can be administered. In the last decade, several agents have been developed that offer possible reduction from the toxicity of a range of anticancer agents. Clinical trials to evaluate these agents are intrinsically more difficult to perform. Standardized assessment and management of chemotherapy-induced toxicities have been required to control these adverse events. Recently, practice guidelines are systematically developed statements to assist the practitioner and patients decision about appropriate management for specific clinical circumstances. Guidelines may be useful in producing better care and decreasing cost. Further clinical research is warranted to address significant questions about the most effective way to assess and treat these adverse events. However, it is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Dr. Rothenberg stated in his recent special article titled "Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel" (J Clin Oncol 19: 3801-3807, 2001) that "Close clinical monitoring, early recognition of toxicities and toxicity syndromes, aggressive therapeutic interventions, and with holding therapy in the presence of unsolved drug-related toxicities is recommended for patients receiving intensive chemotherapy regimens".

Antineoplastic Agents↗